Insider Selling: Axon Enterprise (NASDAQ:AXON) Insider Sells 1,797 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) insider Jeffrey Kunins sold 1,797 shares of Axon Enterprise stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total transaction of $968,996.31. Following the completion of the sale, the insider owned 83,485 shares in the company, valued at approximately $45,017,616.55. This trade represents a 2.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Axon Enterprise Trading Up 1.1%

NASDAQ AXON traded up $5.80 during trading on Wednesday, hitting $543.55. The company had a trading volume of 550,852 shares, compared to its average volume of 708,478. The company’s fifty day moving average is $648.77 and its 200-day moving average is $724.08. Axon Enterprise, Inc has a one year low of $469.24 and a one year high of $885.91. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The company has a market cap of $42.89 billion, a price-to-earnings ratio of 172.01, a price-to-earnings-growth ratio of 122.46 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The company had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same quarter in the prior year, the firm earned $1.45 EPS. Axon Enterprise’s quarterly revenue was up 30.6% compared to the same quarter last year. On average, sell-side analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on AXON shares. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday. UBS Group lowered their price objective on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. The Goldman Sachs Group decreased their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada started coverage on shares of Axon Enterprise in a research note on Monday, November 17th. They set an “outperform” rating and a $860.00 price objective on the stock. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $814.00.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors have recently made changes to their positions in the company. Westside Investment Management Inc. raised its holdings in Axon Enterprise by 4.8% in the 2nd quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 13 shares during the last quarter. CVA Family Office LLC boosted its stake in Axon Enterprise by 26.9% during the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. increased its holdings in shares of Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 14 shares in the last quarter. Vicus Capital raised its stake in shares of Axon Enterprise by 3.7% in the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 14 shares during the last quarter. Finally, Evergreen Capital Management LLC raised its stake in shares of Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.